New Alzheimer’s Treatment Kisunla (Donanemab-AZBT) Receives FDA Approval
Introduction
Eli Lilly and Company has received FDA approval for their latest Alzheimer’s disease treatment, Kisunla (donanemab-azbt). This approval marks the first time a treatment targeting amyloid plaques, the excessive buildup of which in the brain results in thinking or memory issues consistent with Alzheimer’s disease, has been approved in the United States. In clinical trials, Kisunla reduced amyloid plaques in Phase III study participants by up to 84% after 18 months of use. This informative article discusses the benefits and potential risks associated with the new treatment, as well as the implications for the future of Alzheimer’s disease research.
The Need for Effective Alzheimer’s Treatment
According to the Alzheimer’s Association, Alzheimer’s disease is currently the 6th leading cause of death in the United States, and an estimated 6.2 million Americans over the age of 65 are currently living with the disease. These numbers are expected to rise as the baby boomer generation ages, making research into effective Alzheimer’s treatments more crucial than ever before.
Kisunla’s Efficacy in Clinical Trials
In Phase III clinical trials, Kisunla was shown to reduce amyloid plaques in study participants by up to 84% after 18 months of use. Even more promisingly, cognitive and functional decline was reduced by up to 35% in comparison to placebo at the 18-month mark, with participants’ risk of progressing to the next clinical stage of the disease reduced by 39%. Kisunla demonstrated particularly strong results in participants who were in the earliest stages of the disease.
Exploring the Potential of Anti-Amyloid Drugs
The Alzheimer’s Drug Discovery Foundation predicts that anti-amyloid drugs like Kisunla have the potential to become standard in the fight against Alzheimer’s disease. And with FDA approval granted for Kisunla, we are likely to see further research and development in this area, as well as the development of new therapies based on the biology of aging, which may target different aspects of the disease.
Possible Side Effects of Treatment
As with any new treatment, there are potential side effects associated with the use of Kisunla. Some patients may experience amyloid-related imaging abnormalities, which can manifest as temporary swelling in different areas of the brain, small spots of bleeding in or on the brain’s surface, or in rare cases, larger areas of bleeding that can be serious or life-threatening. However, in clinical trials, these side effects were infrequent, and most were not serious or long-lasting.
Looking Towards the Future of Alzheimer’s Disease Treatment
With FDA approval for Kisunla, we now have access to a new and potentially groundbreaking treatment for Alzheimer’s disease. While there is still much to be learned about the ways in which this treatment can be used in combination with other therapies to target the disease, there is reason to hope that this approval will mark the beginning of a new era in Alzheimer’s research. As the number of Americans with the disease continues to rise, it is more important than ever that we continue to explore and develop effective treatments for Alzheimer’s disease.
Long-Tail Keywords:
- Alzheimer’s Disease Treatment
- Kisunla Clinical Trials
- Anti-Amyloid Drugs for Alzheimer’s Disease
- Alzheimer’s Disease Side Effects
- Future of Alzheimer’s Disease Research
Originally Post From https://www.pharmtech.com/view/fda-approves-lilly-treatment-early-symptomatic-alzheimer-s-disease
Read more about this topic at
FDA approves treatment for adults with Alzheimer’s disease
FDA approves Eli Lilly’s Alzheimer’s drug Kisunla
